EP3452504A4 - Gegen influenzavirus gerichtete monoklonale dna-antikörper - Google Patents

Gegen influenzavirus gerichtete monoklonale dna-antikörper Download PDF

Info

Publication number
EP3452504A4
EP3452504A4 EP17793413.0A EP17793413A EP3452504A4 EP 3452504 A4 EP3452504 A4 EP 3452504A4 EP 17793413 A EP17793413 A EP 17793413A EP 3452504 A4 EP3452504 A4 EP 3452504A4
Authority
EP
European Patent Office
Prior art keywords
antibodies against
dna antibodies
against influence
influence virus
monoclonal dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17793413.0A
Other languages
English (en)
French (fr)
Other versions
EP3452504A1 (de
Inventor
Sarah Elliott
Ami Patel
Jian Yan
David Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Inovio Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Wistar Institute of Anatomy and Biology
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn, Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals Inc filed Critical University of Pennsylvania Penn
Publication of EP3452504A1 publication Critical patent/EP3452504A1/de
Publication of EP3452504A4 publication Critical patent/EP3452504A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP17793413.0A 2016-05-05 2017-05-05 Gegen influenzavirus gerichtete monoklonale dna-antikörper Pending EP3452504A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662332381P 2016-05-05 2016-05-05
US201662376162P 2016-08-17 2016-08-17
PCT/US2017/031213 WO2017192946A1 (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting influenza virus

Publications (2)

Publication Number Publication Date
EP3452504A1 EP3452504A1 (de) 2019-03-13
EP3452504A4 true EP3452504A4 (de) 2020-07-29

Family

ID=60203613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17793413.0A Pending EP3452504A4 (de) 2016-05-05 2017-05-05 Gegen influenzavirus gerichtete monoklonale dna-antikörper

Country Status (11)

Country Link
US (2) US11851477B2 (de)
EP (1) EP3452504A4 (de)
JP (3) JP7506869B2 (de)
KR (4) KR20220035288A (de)
CN (2) CN110325546B (de)
AU (2) AU2017261305B2 (de)
BR (1) BR112018072708A2 (de)
CA (1) CA3023093A1 (de)
MX (8) MX2018013521A (de)
SG (2) SG10202011021XA (de)
WO (1) WO2017192946A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017261305B2 (en) * 2016-05-05 2024-06-13 Inovio Pharmaceuticals, Inc. DNA monoclonal antibodies targeting influenza virus
CN110167584B (zh) * 2016-11-07 2024-06-07 威斯塔解剖学和生物学研究所 用于针对莱姆病的dna抗体构建体
US12606612B2 (en) * 2019-07-31 2026-04-21 The Wistar Institute Of Anatomy And Biology Multivalent DNA antibody constructs and use thereof
WO2021050986A1 (en) * 2019-09-11 2021-03-18 Modernatx, Inc. Lnp-formulated mrna therapeutics and use thereof for treating human subjects
EP4426730A1 (de) * 2021-11-05 2024-09-11 Dana-Farber Cancer Institute, Inc. Menschliche monoklonale influenza-antikörper mit breiter kreuzreaktion und verfahren zur verwendung davon
WO2025226722A1 (en) * 2024-04-22 2025-10-30 The Wistar Institute Of Anatomy And Biology Dna antibody and immunogen constructs for use in methods of treating and preventing influenza

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101058807A (zh) * 2006-05-26 2007-10-24 神州细胞工程有限公司 一种优化的单克隆抗体
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2017165460A1 (en) * 2016-03-21 2017-09-28 Weiner David B Dna antibody constructs and method of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
CN101541832B (zh) * 2006-09-07 2014-11-12 克鲁塞尔荷兰公司 能中和流感病毒h5n1的人结合分子及其应用
JP5780762B2 (ja) * 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
US8784819B2 (en) * 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
HRP20190714T1 (hr) * 2011-07-18 2019-06-14 Institute For Research In Biomedicine Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
CA2889723A1 (en) 2012-12-13 2014-06-19 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2016089862A1 (en) * 2014-12-01 2016-06-09 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
AU2017261305B2 (en) * 2016-05-05 2024-06-13 Inovio Pharmaceuticals, Inc. DNA monoclonal antibodies targeting influenza virus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101058807A (zh) * 2006-05-26 2007-10-24 神州细胞工程有限公司 一种优化的单克隆抗体
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
WO2015089492A2 (en) * 2013-12-13 2015-06-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
WO2017165460A1 (en) * 2016-03-21 2017-09-28 Weiner David B Dna antibody constructs and method of using same

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CARTON ET AL: "Codon engineering for improved antibody expression in mammalian cells", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, vol. 55, no. 2, 8 September 2007 (2007-09-08), pages 279 - 286, XP022238133, ISSN: 1046-5928, DOI: 10.1016/J.PEP.2007.05.017 *
CORTI D ET AL: "A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 333, no. 6044, 12 August 2011 (2011-08-12), pages 850 - 856, XP002711146, ISSN: 0036-8075, [retrieved on 20110728], DOI: 10.1126/SCIENCE.1205669 *
FLINGAI SELEEKE ET AL: "Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy", SCIENTIFIC REPORTS, NATURE PUBLISHING GROUP, UK, vol. 5, 29 July 2015 (2015-07-29), pages 12616 - 1, XP008179057, ISSN: 2045-2322 *
J. C. KRAUSE ET AL: "A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin", JOURNAL OF VIROLOGY, vol. 85, no. 20, 15 October 2011 (2011-10-15), pages 10905 - 10908, XP055044176, ISSN: 0022-538X, DOI: 10.1128/JVI.00700-11 *
KARUPPIAH MUTHUMANI ET AL: "Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 214, no. 3, 21 March 2016 (2016-03-21), US, pages 369 - 378, XP055650073, ISSN: 0022-1899, DOI: 10.1093/infdis/jiw111 *
L THE AMERICAN SOCIETY OF GENE & CELL THERAPY: "American Society of Gene & Cell Therapy 19th Annual Meeting - May 4-7, 2016 Washington, DC", SCIENTIFIC SYMPOSIUM, vol. 24, 5 May 2016 (2016-05-05), pages i - xiv, XP055661448 *
LEONTIOS PAPPAS ET AL: "Rapid development of broadly influenza neutralizing antibodies through redundant mutations", NATURE, vol. 516, no. 7531, 5 October 2014 (2014-10-05), pages 418 - 422, XP055199456, ISSN: 0028-0836, DOI: 10.1038/nature13764 *
SARAH T. C. ELLIOTT ET AL: "DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections", NPJ VACCINES, vol. 2, no. 1, 6 July 2017 (2017-07-06), XP055661090, DOI: 10.1038/s41541-017-0020-x *
SARAH T.C. ELLIOTT ET AL: "Abstract 433. DNA Monoclonal Antibodies Target Influenza Virus In Vivo", MOLECULAR THERAPY - SUPPLEMENT 1, May 2016 (2016-05-01), pages S171 - S172, XP055661431 *
See also references of WO2017192946A1 *
SELEEKE FLINGAI: "University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Engineered DNA-Mediated Antibody Gene Transfer for Prophylaxis Against Infectious Diseases Engineered DNA-Mediated Antibody Gene Transfer for Prophylaxis Against Infectious Diseases", 1 January 2016 (2016-01-01), XP055698819, Retrieved from the Internet <URL:https://pdfs.semanticscholar.org/73bf/994fd8b4ea28359af0c82df9f0dd2a23d67e.pdf?_ga=2.33074750.1815083394.1590572847-161144235.1590435137> [retrieved on 20200527] *
YAMAZAKI TATSUYA ET AL: "Passive Immune-Prophylaxis against Influenza Virus Infection by the Expression of Neutralizing Anti-Hemagglutinin Monoclonal Antibodies from Plasmids", JAPANESE JOURNAL OF INFECTIOUS DISEASES, vol. 64, no. 1, 31 January 2011 (2011-01-31), JP, pages 40 - 49, XP093187576, ISSN: 1344-6304, DOI: 10.7883/yoken.64.40 *

Also Published As

Publication number Publication date
US20190135899A1 (en) 2019-05-09
MX2024006290A (es) 2024-08-26
CN110325546B (zh) 2024-03-19
AU2017261305B2 (en) 2024-06-13
MX2024006289A (es) 2024-08-26
KR102375324B1 (ko) 2022-03-18
BR112018072708A2 (pt) 2019-02-19
AU2017261305A1 (en) 2018-12-20
JP2022116034A (ja) 2022-08-09
CN118109478A (zh) 2024-05-31
KR20230125851A (ko) 2023-08-29
JP2025081330A (ja) 2025-05-27
AU2024203297A1 (en) 2024-06-13
WO2017192946A1 (en) 2017-11-09
US11851477B2 (en) 2023-12-26
US20240150442A1 (en) 2024-05-09
MX2024006291A (es) 2024-08-26
MX2018013521A (es) 2019-06-10
MX2024006293A (es) 2024-08-26
JP7506869B2 (ja) 2024-06-27
SG11201809783RA (en) 2018-12-28
KR20190035614A (ko) 2019-04-03
MX2024006295A (es) 2024-08-26
KR20240155978A (ko) 2024-10-29
MX2024006292A (es) 2024-08-26
MX2024000118A (es) 2024-01-22
CA3023093A1 (en) 2017-11-09
WO2017192946A8 (en) 2018-12-27
JP2019521702A (ja) 2019-08-08
CN110325546A (zh) 2019-10-11
AU2017261305A8 (en) 2019-08-08
KR20220035288A (ko) 2022-03-21
SG10202011021XA (en) 2020-12-30
EP3452504A1 (de) 2019-03-13

Similar Documents

Publication Publication Date Title
IL272227A (en) Anti-tigit antibodies
IL269405A (en) Anti-sirp alpha antibodies
IL268620A (en) Anti-lag3 antibodies
IL263452A (en) Anti-ige antibodies
IL263834A (en) Anti-pd-l1 antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (de) Anti-il1rap-antikörper
EP3569709A4 (de) Anti-gpc3-antikörper
DK3964529T3 (da) Ikke-blokerende pd1-specifikke antistoffer
DK3455257T3 (da) Anti-pd-l1-antistoffer
EP3481869A4 (de) Anti-cd73-antikörper
EP3426686C0 (de) Humanisierte anti-pacap-antikörper und verwendungen davon
EP3691447A4 (de) Anti-transthyretin-antikörper
DK3344654T3 (da) Anti-lag-3-antistoffer
EP3319984C0 (de) Tau-bindende antikörper
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3250593T3 (da) Anti-transthyretin-antistoffer
EP3319983C0 (de) Tau-bindende antikörper
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3487518A4 (de) Gegen ve-ptp (hptp-ss) gerichtete humanisierte monoklonale antikörper
DK3452513T3 (da) Humaniserede anti-il-ir3-antistoffer
EP3452504A4 (de) Gegen influenzavirus gerichtete monoklonale dna-antikörper
EP3567053A4 (de) Monoklonaler anti-claudin-2-antikörper
IL257354A (en) Antibodies and assays for detection of cd37

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20200207BHEP

Ipc: C07K 16/08 20060101AFI20200207BHEP

Ipc: A61K 48/00 20060101ALI20200207BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20200625

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/00 20060101ALI20200619BHEP

Ipc: C07K 16/08 20060101AFI20200619BHEP

Ipc: A61K 48/00 20060101ALI20200619BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230606

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240729